Institutional members access full text with Ovid®

Share this article on:

Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?

Peintinger, Florentia

Current Opinion in Obstetrics & Gynecology: February 2014 - Volume 26 - Issue 1 - p 21–26
doi: 10.1097/GCO.0000000000000041
BREAST CANCER: Edited by Gottfried E. Konecny

Purpose of review: In this article, recent developments with molecular profiling in breast cancer and future directions will be highlighted.

Recent findings: Gene-expression profiling revealed four major biologic subtypes that reflect intertumoral heterogeneity of breast cancer and have led to the development of prognostic tools to facilitate adequate treatment in early breast cancer. A number of commercially available prognostic tests have been introduced for implementation in clinical routine. Also, predictive tools and approaches to characterize molecular portraits of metastatic breast cancer in order to overcome treatment resistance have been investigated. Efforts to identify the quantity and quality of clonal selection and genomic variability through modern genomic profiling led successfully to new insights into targeted treatment with more effective drugs and the promise to overcome resistance.

Summary: Multigene approaches and novel microarray platforms such as the next-generation sequencing technology are feasible in clinical practice in order to assess the prognosis more precisely and to identify new molecular targets for developing more effective drugs in the near future.

Correspondence to Florentia Peintinger, MD, Institute of Pathology, Medical University Graz, Auenbruggerplatz 25, 8036 Graz, Austria. Tel: +43 664 35 57 865; fax: +43 316 82 21 88; e-mail: florentia.peintinger@medunigraz.at

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins